
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has provided an update on its meeting with …
Read More